Abstract:Background Ovarian cancer (OVCA) stands as one of the most fatal gynecological malignancies. Honokiol (HNK) has been substantiated by numerous studies for its anti‐tumor activity against malignancies including OVCA. Consequently, this work was designed to elucidate the impact of HNK‐mediated modulation of the YAP/TAZ pathway on the biological functions of OVCA cells. Methods OVCA cells were subjected to treatment with varying concentrations (0, 25, 50, 75, and 100 μM) of HNK, concomitant with the administration of YAP agonist (XMU). Assessment of cellular viability was executed employing the CCK‐8 assay, while quantification of cellular proliferation transpired via colony formation assays. Apoptosis was ascertained using flow cytometry, and expression of apoptosis‐related proteins (caspase‐3, Bcl‐2, Bax), EMT‐related proteins (E‐cadherin, N‐cadherin), migration‐associated proteins (MMP‐2, MMP‐9), and YAP/TAZ pathway‐related proteins was evaluated by western blot. Transwell experiments were conducted to assess cellular migratory and invasive propensities. Xenograft tumor models were built to observe tumor growth (volume and weight), apoptosis was assessed by TUNEL staining, and Ki67 expression was evaluated through IHC. Results HNK exerted inhibitory effects on the viability and proliferative capacity of OVCA cells, elicited apoptotic responses, curtailed the migratory and invasive tendencies of cells, and downregulated the YAP/TAZ pathway. Stimulation with YAP agonist (XMU‐MP‐1) partially attenuated the impacts of HNK on OVCA cell biology. Experiments in vivo confirmed that HNK inhibited OVCA tumor growth. Conclusion The outcomes of this investigation conclusively established that HNK orchestrated the modulation of the YAP/TAZ pathway, thereby exerting control over the malignant phenotypic manifestations of OVCA cells. The ascertained function of HNK in restraining cellular proliferation and tumor progression provided novel evidence of its anti‐proliferative activity within OVCA cells.

Novel 1,3,4-Thiadiazole/oxadiazole-linked Honokiol Derivatives Suppress Cancer Via Inducing PI3K/Akt/mTOR-dependent Autophagy

Honokiol Induces Apoptosis and Autophagy Via the ROS/ERK1/2 Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo.

Honokiol Augments the Anti-Cancer Effects of Oxaliplatin in Colon Cancer Cells

Anti-proliferative Activity and Structure-Activity Relationship of Honokiol Derivatives.

Structural Modification of Honokiol, A Biphenyl Occurring in Magnolia Officinalis: the Evaluation of Honokiol Analogues As Inhibitors of Angiogenesis and for Their Cytotoxicity and Structure-Activity Relationship

Honokiol: a potent chemotherapy candidate for human colorectal carcinoma.

Honokiol Induces Ferroptosis In Colon Cancer Cells By Regulating Gpx4 Activity

Honokiol: a Promising Small Molecular Weight Natural Agent for the Growth Inhibition of Oral Squamous Cell Carcinoma Cells.

Honokiol, a natural therapeutic candidate, induces apoptosis and inhibits angiogenesis of ovarian tumor cells.

Honokiol: A naturally occurring lignan with pleiotropic bioactivities

Formylated Honokiol Analogs Showed Antitumor Activity Against Lung Carcinoma

Honokiol Induces Apoptosis, G1 Arrest, and Autophagy in KRAS Mutant Lung Cancer Cells

Honokiol Exhibits Anti-Tumor Effects in Breast Cancer by Modulating the miR-148a-5p-CYP1B1 Axis

Semi-synthesis and anti-proliferative activity evaluation of novel analogues of Honokiol.

Mitochondrial Targeting Derivatives of Honokiol Enhanced Selective Antitumor Activity in Nci-H446 Cellsand Decreased in Vivo Toxicity in Caenorhabditis Elegans

Novel Diosgenin Derivatives Containing 1,3,4-Oxadiazole/thiadiazole Moieties As Potential Antitumor Agents: Design, Synthesis and Cytotoxic Evaluation

Use of honokiol in lung cancer therapy: a mini review of its pharmacological mechanism

Synthesis and evaluation of new compounds bearing 3-(4-aminopiperidin-1-yl)methyl magnolol scaffold as anticancer agents for the treatment of non-small cell lung cancer via targeting autophagy

Synthesis and antitumor activity of α,β-unsaturated carbonyl moiety- containing oleanolic acid derivatives targeting PI3K/AKT/mTOR signaling pathway

Honokiol regulates ovarian cancer cell malignant behavior through YAP/TAZ pathway modulation

Anticancer Effects of Honokiol Via Mitochondrial Dysfunction Are Strongly Enhanced by the Mitochondria-Targeting Carrier Berberine